who invented retatrutide 10 mg — research material — PEPerchini Scientific Medscape | Retatrutide, an investigational

Consistency matters more than intensity

In fact, early research suggests that GLP-1 receptor agonists may decrease the risk of obesity-associated cancers

In two years, without intervention, most patients do not stay the same weightthey gain more

Its worth noting that because retatrutide targets three hormone pathways instead of one or two, some people in trials experienced more pronounced digestive side effects compared to other weight loss medications

These positive results prompted the first clinical trial of exenatide in treating patients with IIH

And among adults whove ever taken GLP-1, cost was one of the most common reasons for discontinuing, at 14%